Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 3/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.39 |
| ▸ | PDE9A | O76083 | 7/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20360605 | 0.88 | CDK5 (0.40) | CDK5CDK5R1PDE9AKDM4ESMN1; SMN2 | |
| SCHEMBL23069400 | 0.80 | TYMP (0.36) | CDK5CDK5R1PDE9AKDM4ESMN1; SMN2 | |
| SCHEMBL23069401 | 0.80 | TYMP (0.36) | CDK5CDK5R1PDE9AKDM4ESMN1; SMN2 | |
| SCHEMBL18065052 | 0.78 | HDAC1 (0.40) | CDK5CDK5R1NPC1RAB9A | |
| SCHEMBL20407788 | 0.77 | KDM4E (0.47) | CDK5CDK5R1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL20052011 | 0.77 | KDM4E (0.47) | CDK5CDK5R1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL441421 | 0.75 | TYMP (0.48) | KDM4ETYMP | |
| SCHEMBL13443494 | 0.75 | KDM4E (0.45) | CDK5CDK5R1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL31273672 | 0.75 | KDM4E (0.39) | PDE9AKDM4ESMN1; SMN2NPC1LMNA | |
| SCHEMBL27041198 | 0.75 | HPRT1 (0.40) | PDE9AKDM4ESMN1; SMN2NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151991-A1 | RNAI AGENTS FOR INHIBITING INFLUENZA A VIRAL GENE EXPRESSION, COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024148329-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-07-11 | — | — | WO | disclosed |
| EP-3784269-B1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ARROWHEAD PHARMACEUTICALS INC (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240175019-A1 | Skeletal Muscle Delivery Platforms and Methods of Use | Arrowhead Pharmaceuticals, Inc. | 2024-05-30 | — | — | US | disclosed |
| US-20240141351-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-05-02 | — | — | US | disclosed |
| WO-2024086633-A1 | RNAI AGENTS FOR INHIBITING EXPRESSION OF DM1 PROTEIN KINASE (DMPK) COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-4352229-A1 | RNAI AGENTS FOR INHIBITING EXPRESSION OF MUCIN 5AC (MUC5AC), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240076270-A1 | INTEGRIN LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2024-03-07 | — | — | US | disclosed |
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4319765-A1 | RNAI AGENTS FOR INHIBITING EXPRESSION OF RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS, COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-3271482-A2 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF FACTOR XII | Arrowhead Pharmaceuticals, Inc. (US) | 2018-01-24 | — | — | EP | disclosed |
| US-9803205-B2 | Compositions and methods for inhibiting gene expression of factor XII | Arrowhead Pharmaceuticals, Inc. (US) | 2017-10-31 | — | — | US | disclosed |
| WO-2017059223-A9 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-08-17 | — | — | WO | disclosed |
| US-20170096665-A1 | Compositions and Methods for Inhibiting Gene Expression of LPA | Arrowhead Pharmaceuticals, Inc. | 2017-04-06 | — | — | US | disclosed |
| WO-2016196239-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF HIF2ALPHA | Arrowhead Pharmaceuticals, Inc. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20160348107-A1 | Compositions and Methods for Inhibiting Gene Expression of Hif2alpha | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2016-12-01 | — | — | US | disclosed |
| WO-2016149020-A1 | RNA INTERFERENCE AGENTS | ARROWHEAD RESEARCH CORPORATION (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160272978-A1 | Compositions and Methods for Inhibiting Gene Expression of Factor XII | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2016-09-22 | — | — | US | disclosed |
| WO-2016149331-A2 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF FACTOR XII | ARROWHEAD RESEARCH CORPORATION (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160272970-A1 | RNA Interference Agents | Arrowhead Pharmaceuticals, Inc. | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | SOD1, SOD3, SMN1; SMN2 | CDK5 2650/4885CDK5R1 2202/4885PDE9A 4390/4885 |
| US-20160348107-A1 | Compositions and Methods for Inhibiting Gene Expression of Hif2alpha | EPAS1, HIF1AN, EGLN2 | CDK5 4296/4885CDK5R1 3296/4885PDE9A 2846/4885 |
| US-20240076270-A1 | INTEGRIN LIGANDS AND USES THEREOF | ITGAV, ITGA6, ITGB6 | CDK5 4388/4885CDK5R1 3617/4885PDE9A 3858/4885 |
| US-20240175019-A1 | Skeletal Muscle Delivery Platforms and Methods of Use | MUSK, MYLK2, ITGB6 | CDK5 2055/4885CDK5R1 1131/4885PDE9A 935/4885 |
| US-20240141351-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | SERPINA2, SERPINC1, SERPINA3 | CDK5 4398/4885CDK5R1 3567/4885PDE9A 4760/4885 |
| US-20160272978-A1 | Compositions and Methods for Inhibiting Gene Expression of Factor XII | F12, F13A1, F11 | CDK5 2986/4885CDK5R1 1681/4885PDE9A 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.